# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...
– Ocrevus Zunovo™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints, li...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 ...
– Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and eff...
Benchmark analyst Robert Wasserman reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $60 price target.